Compare Crispr Therapeutics AG (CRSP) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Ferrari NV — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Ferrari NV trades at $389.91 (market cap $67.35B). The key difference: Ferrari NV is far larger — about 13.8× Crispr Therapeutics AG's market cap, and Ferrari NV pays a 1.09% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Ferrari NV for 126 Days on average.
| CRSP | RACE | |
|---|---|---|
Market Cap | $4.88B | $67.35B |
Volume | 2,861,747 | 390,618 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $436.54 |
52-Week Low | $44.34 | $314.63 |
Typical Hold Time | 77 Days | 126 Days |
Enterprise Value | $3.30B | $69.22B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Ferrari (RACE) trades at $389.91, up 0.91% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $7.15B and $1.60B in 2025, respectively. The company maintains high profitability margins and a robust balance sheet, though cash flow trends show recent volatility. Recent news highlights a share buyback program and strategic partnerships, supporting investor confidence.
The outlook for Ferrari remains positive due to consistent earnings beats, high margins, and analyst optimism, with a consensus price target of $462.75 implying 18.7% upside. Risks include valuation multiples above industry averages, competitive pressures in the luxury automotive sector, and macroeconomic sensitivity. Institutional buying activity and a dominant buy rating from analysts underscore long-term growth potential, but investors should monitor execution on future earnings and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
